文献速递糖尿病

联邦医疗保险按服务收费受益人中先进糖尿病技术采用的不平等

Inequity in Adoption of Advanced Diabetes Technologies Among Medicare Fee-for-service Beneficiaries.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究基于2017-2019年联邦医疗保险按服务收费数据库,分析1型糖尿病受益人胰岛素泵和连续血糖监测(CGM)使用率的种族-民族差异。结果显示所有组使用率均上升,但白人胰岛素泵使用率从14%升至18%,黑人和其他受益人始终低于5%;2019年白人使用泵的比例为57%,黑人33.1%,其他30.3%(P<0.001)。黑人-白人技术采用差距在2017-2019年间扩大。

要点

  • 2017-2019年所有种族-民族组CGM和胰岛素泵使用率均上升。
  • 2019年白人泵使用率57%,黑人33.1%,其他30.3%(P<0.001)。
  • 黑人-白人糖尿病技术采用差距在2017-2019年间扩大。

核心结论

  • 1型糖尿病管理存在显著的种族-民族相关差异,黑人-白人受益人糖尿病技术采用差距在2017-2019年间扩大。

研究设计与样本

  • 基于联邦医疗保险按服务收费数据库2017-2019保险年份的回顾性分析,纳入每年至少1次住院或2次门诊索赔的1型糖尿病受益人,按种族-民族确定胰岛素泵和CGM使用率,并比较2019年技术使用者与非使用者的特征。

主要发现

  • 2017-2019年所有组CGM和胰岛素泵使用率均增加,黑人和其他受益人胰岛素泵使用率<5%,白人从14%升至18%。
  • 2019年白人泵使用率为57%,黑人33.1%,其他30.3%(P<0.001)。
  • 黑人患者因残疾/终末期肾病或联邦医疗保险/医疗补助资格而符合条件的可能性高于白人(均P<0.001),无论是否使用技术。
  • 技术使用者与非使用者之间除就诊内分泌科外,所有评估因素均存在显著种族-民族差异(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Health inequity is often associated with race-ethnicity. OBJECTIVE: To determine the prevalence of insulin pump therapy and continuous glucose monitoring (CGM) among Medicare beneficiaries with type 1 diabetes (T1D) by race-ethnicity, and to compare diabetes-related technology users with nonusers. DESIGN: The prevalence of technology use (pump, CGM) was determined by race-ethnicity for enrollees in coverage years (CY) 2017-2019 in the Medicare fee-for-service database. Using CY2019 data, technology users were compared with nonusers by race-ethnicity, sex, average age, Medicare eligibility criteria, and visit to an endocrinologist. SETTING: Community. PATIENTS OR OTHER PARTICIPANTS: Beneficiaries with T1D and at least 1 inpatient or 2 outpatient claims in a CY. INTERVENTION(S): Pump or CGM therapy, visit to an endocrinologist. MAIN OUTCOME MEASURE(S): Diabetes-related technology use by race-ethnicity groups. RESULTS: Between 2017 and 2019, CGM and insulin pump use increased among all groups. Prevalence of insulin pump use was < 5% for Black and Other beneficiaries yet increased from 14% to 18% among White beneficiaries. In CY2019, 57% of White patients used a pump compared with 33.1% of Black and 30.3% of Other patients (P < 0.001). Black patients were more likely than White patients to be eligible because of disability/end-stage renal disease or to be Medicare/Medicaid eligible (both P < 0.001), whether using technology or not. Significant race-ethnicity differences (P < 0.001) existed between technology users and nonusers for all evaluated factors except visiting an endocrinologist. CONCLUSIONS: Significant race-ethnicity associated differences existed in T1D management. The gap in diabetic technology adoption between Black and White beneficiaries grew between 2017 and 2019.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wherry K, Zhu C, Vigersky RA, et al. Inequity in Adoption of Advanced Diabetes Technologies Among Medicare Fee-for-service Beneficiaries. J Clin Endocrinol Metab. 2022. PMID: 34910144. doi:10.1210/clinem/dgab869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。